(Q51795458)

12 April 2018

title

Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. (English)

1 reference

12 April 2018

chronic eosinophilic leukemia

1 reference

1 reference

1 reference

11

1 reference

12 April 2018

Nicholas Cross

13

1 reference

12 April 2018

Claudia Schoch

6

object named as

Claudia Schoch

1 reference

12 April 2018

10

Torsten Haferlach

1 reference

12 April 2018

5

Georgia Metzgeroth

1 reference

12 April 2018

3

Susanne Schnittger

1 reference

12 April 2018

8

Philipp Erben

1 reference

12 April 2018

author name string

Christoph Walz

1

1 reference

12 April 2018

Claire Curtis

2

1 reference

12 April 2018

Beate Schultheis

4

1 reference

12 April 2018

Eva Lengfelder

7

1 reference

12 April 2018

Martin C Müller

9

1 reference

12 April 2018

Rüdiger Hehlmann

12

1 reference

12 April 2018

Andreas Reiter

14

1 reference

12 April 2018

publication date

1 October 2006

1 reference

12 April 2018

Genes, Chromosomes and Cancer

published in

1 reference

12 April 2018

volume

45

1 reference

12 April 2018

issue

10

1 reference

12 April 2018

page(s)

950-956

1 reference

12 April 2018

The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia

cites work

1 reference

7 January 2021

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

1 reference

7 January 2021

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

7 January 2021

A centrosomal mechanism involving CDK5RAP2 and CENPJ controls brain size

1 reference

7 January 2021

The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene

1 reference

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

7 January 2021

Cloning of three novel neuronal Cdk5 activator binding proteins

1 reference

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

7 January 2021

Tyrosine kinase fusion genes in chronic myeloproliferative diseases.

1 reference

7 January 2021

Chronic myeloproliferative disorders: a tyrosine kinase tale.

1 reference

7 January 2021

Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome.

1 reference

7 January 2021

The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins

1 reference

7 January 2021

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

7 January 2021

Oncogenic derivatives of platelet-derived growth factor receptors.

1 reference

7 January 2021

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

7 January 2021

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

1 reference

7 January 2021

Tyrosine kinases as targets for cancer therapy

1 reference

7 January 2021

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

1 reference

7 January 2021

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

1 reference

7 January 2021

PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation

1 reference

7 January 2021

Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease

1 reference

7 January 2021

Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology

1 reference

7 January 2021

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

7 January 2021

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature

1 reference

7 January 2021

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

1 reference

7 January 2021

Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia

1 reference

7 January 2021

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

1 reference

7 January 2021

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

7 January 2021

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

7 January 2021

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia

1 reference

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

7 January 2021

Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta

1 reference

7 January 2021

Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation

1 reference

7 January 2021

Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec

1 reference

7 January 2021

N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders.

1 reference

7 January 2021

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

1 reference

7 January 2021

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

7 January 2021

The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1.

1 reference

7 January 2021

Identification of a common protein association region in the neuronal Cdk5 activator

1 reference

7 January 2021

Identifiers

DOI

10.1002/GCC.20359

1 reference

12 April 2018

1 reference

12 April 2018